The chemokine CX3CL1 improves trastuzumab efficacy in HER2 low-expressing cancer in vitro and in vivo

Tobias F. Dreyer, Sabine Kuhn, Christoph Stange, Nadine Heithorst, Daniela Schilling, Jil Jelsma, Wolfgang Sievert, Stefanie Seitz, Stefan Stangl, Alexander Hapfelmeier, Aurelia Noske, Anja K. Wege, Wilko Weichert, J. Eurgen Ruland, Manfred Schmitt, Julia Dorn, Marion Kiechle, Ute Reuning, Viktor Magdolen, Gabriele MulthoffHolger Bronger

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


A crucial mode of action of trastuzumab is the labeling of HER2-positive (HER2+) tumor cells for the eradication by natural killer (NK) cells, a process called antibody-dependent cellular cytotoxicity (ADCC). However, despite widespread HER2 expression among cancer entities, only a fraction, with robust HER2 overexpression, benefits from trastuzumab therapy. ADCC requires both sufficient lymphocytic infiltration and close binding of the immune cells to the antibody-tagged tumor cells. We hypothesized that the chemokine CX3CL1 could improve both processes, as it is synthesized as a membrane-bound, adhesive form that is eventually cleaved into a soluble, chemotactic protein. Here, we show that CX3CL1 overexpression is a positive prognostic marker in breast cancer. CX3CL1 overexpression attracted tumor-suppressive lymphocytes, including NK cells, and inhibited tumor growth and lung metastasis in the syngeneic 4T1 breast cancer mouse model. In HER2+ SKBR3, MDA-MB-453, and HT-29 tumor cells, CX3CL1 overexpression increased NK cell- mediated cytotoxicity in vitro and acted synergistically with trastuzumab. Even though CX3CL1 did not further improve trastuzumab efficacy in vivo in the trastuzumab-sensitive MDA-MB-453 model, it compensated for NK-cell depletion and prolonged survival. In the HER2 low-expressing HT-29 model, however, CX3CL1 overexpression not only prolonged survival time but also overcame trastuzumab resistance in a partly NK cell-dependent manner. Taken together, these findings identify CX3CL1 as a feasible pharmacologic target to enable trastuzumab therapy in HER2 low-expressing cancers and render it a potential predictive biomarker to determine therapy responders.

Original languageEnglish
Pages (from-to)779-789
Number of pages11
JournalCancer Immunology Research
Issue number7
StatePublished - Jul 2021


Dive into the research topics of 'The chemokine CX3CL1 improves trastuzumab efficacy in HER2 low-expressing cancer in vitro and in vivo'. Together they form a unique fingerprint.

Cite this